Abstract:This review article provides an overview of the recent advancements of imidazo[1,2‐a]pyridine (IP) derivatives such as Akt, phosphoinositide‐3‐kinase (PI3K), tubulin, and c‐MET inhibitors. The structures of the compounds, their structure–activity relationships, and docking studies were added to assist researchers in synthesizing precisely targeted drugs, utilizing IP as the main scaffold to treat cancer. Cancer ranks among the most life‐threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target‐based, have a higher potency, and have minimal toxicity. The imidazo[1,2‐a]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide‐3‐kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure–activity‐relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.

An overview of pyridazin-3(2 H)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer

Structural Activity Relationship-based Medicinal perceptions of Pyrazoline derivatives as Anti-Cancer Agents: A Review

An Overview of Pyridazinone Analogs: Chemical and Pharmacological Potential

Medicinal attributes of pyridine scaffold as anticancer targeting agents

Pyrimidine: An elite heterocyclic leitmotif in drug discovery‐synthesis and biological activity

Pyrazole Paradigms: Unveiling Synthetic Pathways and Unraveling Anti-Cancer Potential

A critical review on recent trends on pharmacological applications of pyrazolone endowed derivatives

A review on pyrimidine‐based derivatives: Synthesis and their biological application

Pyrrole: An Essential Framework in the Development of Therapeutic Agents and Insightful Analysis of Structure‐Active Relationships

Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review

Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules

Pyrazole Derivatives with NCN Junction and their Biological Activity: A Review

Insights into medicinal attributes of imidazo[1,2‐a]pyridine derivatives as anticancer agents

Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents

Recent Advancements and Developments in the Biological Importance of Pyrimido[4,5‐b]Quinoline Scaffolds

Recent Advances in Pyrimidine-Based Drugs

Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment

Pyrazole Derivatives As Antitumor, Anti-Inflammatory and Antibacterial Agents

Innovative Pyrazole Hybrids: A New Era in Drug Discovery and Synthesis

Targeted Development of Pyrazoline Derivatives for Neurological Disorders: A Review